Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer

Authors :: Gabriela Plesa
Anne Marie Nelson
J. Joseph Melenhorst
Gregory L. Beatty
Bruce L. Levine
Maureen McGarvey
Drew A. Torigian
Simon F. Lacey
Carl H. June
Mark H. O'Hara
Source :: Journal of Clinical Oncology. 33:3007-3007
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: 3007 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive microenvironment with a scarcity of effector T cells. Adoptive T cell therapy to restore anti-tumor...

Subjects :: Oncology
Antitumor activity
Cancer Research
medicine.medical_specialty
Chemotherapy
endocrine system diseases
Effector
business.industry
T cell
medicine.medical_treatment
digestive system diseases
Chimeric antigen receptor
medicine.anatomical_structure
Refractory
Internal medicine
Metastatic pancreatic cancer
Medicine
In patient
business

Full Text Access

Tools